Biotechnology Industry Organization, corporate social responsibility, extraordinary pricing, National Organization for Rare Disorders, Inc., orphan drugs, patient access, Pharmaceutical Research and Manufacturers of America, pharmaceutical industry, pharmaceutical pricing, reputation,
Conventional cost-effectiveness analysis-i.e., assessing pharmaceuticals through a cost per quality-...
Rare disease drug research and development has intensified over the past two decades and has been tr...
Orphan drugs: challenges for economic evaluation • Public-private partnerships for health and develo...
The business model under which the pharmaceutical industry has operated in the recent past has becom...
Orphan drugs and diseases are a neglected academic and scientific research area. The Orphan Drug Act...
Abstract Background More than ...
Abstract Pricing and reimbursement of orphan drugs are an issue of high priority for policy makers, ...
International audienceAbout 5000 identified diseases are classed as orphan because of the lack of di...
Concerns about the high cost of orphan drugs has led to questions being asked about the generosity o...
Abstract Background The Orphan Drug Act is an important piece of legislation that uses financial inc...
The aim of this paper is to discuss the common features and specificity of Corporate Social Responsi...
The work aims to propose preliminary reflections upon a managerial view concerning the open issue of...
Corporate social responsibility (CSR) has major implications for pricing decisions in some markets. ...
© 2019 Portfolio Management Research. All rights reserved. Thanks to a combination of scientific adv...
On the thirty-fifth anniversary of the adoption of the Orphan Drug Act (ODA), we describe the enormo...
Conventional cost-effectiveness analysis-i.e., assessing pharmaceuticals through a cost per quality-...
Rare disease drug research and development has intensified over the past two decades and has been tr...
Orphan drugs: challenges for economic evaluation • Public-private partnerships for health and develo...
The business model under which the pharmaceutical industry has operated in the recent past has becom...
Orphan drugs and diseases are a neglected academic and scientific research area. The Orphan Drug Act...
Abstract Background More than ...
Abstract Pricing and reimbursement of orphan drugs are an issue of high priority for policy makers, ...
International audienceAbout 5000 identified diseases are classed as orphan because of the lack of di...
Concerns about the high cost of orphan drugs has led to questions being asked about the generosity o...
Abstract Background The Orphan Drug Act is an important piece of legislation that uses financial inc...
The aim of this paper is to discuss the common features and specificity of Corporate Social Responsi...
The work aims to propose preliminary reflections upon a managerial view concerning the open issue of...
Corporate social responsibility (CSR) has major implications for pricing decisions in some markets. ...
© 2019 Portfolio Management Research. All rights reserved. Thanks to a combination of scientific adv...
On the thirty-fifth anniversary of the adoption of the Orphan Drug Act (ODA), we describe the enormo...
Conventional cost-effectiveness analysis-i.e., assessing pharmaceuticals through a cost per quality-...
Rare disease drug research and development has intensified over the past two decades and has been tr...
Orphan drugs: challenges for economic evaluation • Public-private partnerships for health and develo...
DOI
Add to ORKG